Canada markets open in 5 hours 35 minutes
  • S&P/TSX

    19,969.19
    -4.03 (-0.02%)
     
  • S&P 500

    3,963.51
    +29.59 (+0.75%)
     
  • DOW

    33,781.48
    +183.56 (+0.55%)
     
  • CAD/USD

    0.7336
    -0.0024 (-0.32%)
     
  • CRUDE OIL

    71.95
    +0.49 (+0.69%)
     
  • BTC-CAD

    23,460.80
    +380.90 (+1.65%)
     
  • CMC Crypto 200

    405.77
    +11.09 (+2.81%)
     
  • GOLD FUTURES

    1,802.70
    +1.20 (+0.07%)
     
  • RUSSELL 2000

    1,818.29
    +11.39 (+0.63%)
     
  • 10-Yr Bond

    3.4910
    0.0000 (0.00%)
     
  • NASDAQ futures

    11,681.75
    +36.25 (+0.31%)
     
  • VOLATILITY

    22.60
    -0.08 (-0.35%)
     
  • FTSE

    7,461.78
    -10.39 (-0.14%)
     
  • NIKKEI 225

    27,901.01
    +326.58 (+1.18%)
     
  • CAD/EUR

    0.6942
    -0.0024 (-0.34%)
     

Gilead Sciences: Mother of Three Shares Her CAR T-Cell Therapy Journey: Kelly's Story

NORTHAMPTON, MA / ACCESSWIRE / September 30, 2022 / Kelly was getting ready to leave on a trip to celebrate her 25th wedding anniversary when she started experiencing pain in her abdomen and discovered a lump on her neck. When the pain progressed to the point where it got worse when she laid down, she asked her husband, an emergency room doctor, what he thought. After a few phone calls to his colleagues working in oncology, they went to see a lymphoma specialist and Kelly underwent a CAT scan the day before her trip.

The doctor called Kelly and her husband during their vacation and said they needed to talk when she got back. Kelly says she "just knew" it was cancer. When she returned from the trip, she was diagnosed with stage four non-Hodgkin lymphoma.

"It was earth shattering. Your whole world comes crashing down," she explains. "When cancer hits, nothing else matters."

Kelly received six rounds of chemotherapy - one round every three weeks. But shortly after the chemo treatments ended, her pain returned. Her cancer had not responded to the initial treatment. Kelly's oncologist then recommended a different, stronger chemotherapy, but her cancer didn't respond to the second treatment.

After two failed treatments, Kelly's oncologist told her about chimeric antigen receptor (CAR) T-cell therapy: a form of therapy custom-made for each patient using their own immune cells to fight their cancer. She was optimistic and agreed to pursue CAR T with her oncologist's support.

Following CAR T-cell therapy in 2021, Kelly has not needed additional cancer treatment. It was the first sign of relief for Kelly and her family since the diagnosis. Her children credit staying positive as helping them get through it.

"No matter how bad it gets, don't ever give up. Hope is the one thing that just keeps you going," says Kelly.

Watch the video above to see Kelly's full journey.

Originally published by Gilead Sciences

Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: http://www.gilead.com/
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View source version on accesswire.com:
https://www.accesswire.com/718312/Gilead-Sciences-Mother-of-Three-Shares-Her-CAR-T-Cell-Therapy-Journey-Kellys-Story